FindTrial
Sign In

Integrative pan-cancer analysis reveals the role of OSGIN2 in prognosis assessment, immune regulation, and drug resistance mechanisms.

Integrative pan-cancer analysis reveals the role of OSGIN2 in prognosis assessment, immune regulation, and drug resistance mechanisms.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124565
Enrollment
Unknown
Registered
2026-05-13
Start date
2025-11-12
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung adenocarcinoma

Interventions

Tissue samples before and after EGFR-TKI:None

Sponsors

Army Medical Center of PLA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed primary LUAD patients (AJCC 8th edition stage I-III); 2. Complete surgical resection specimens and follow-up data; 3. Lung cancer samples with nine-gene testing showing EGFR mutation; 4. Preoperative treatment with EGFR-TKI.

Exclusion criteria

Exclusion criteria: 1. Merge with other malignant tumors; 2. The sample quality does not meet the testing requirements (such as RNA integrity number RIN<7)

Design outcomes

Primary

MeasureTime frame
OSGIN2 protein expression;PD-L1 expression;CD8+ T cell density;Overall survival (OS);—

Secondary

MeasureTime frame
Progression-free survival (PFS);—

Countries

China

Contacts

Public ContactChen Yan

Army Medical Center of PLA

blk-sy@tmmu.edu.cn+86 23 68746715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026